The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Comprehensive Research Report: CLCN7 Gene (UniProt P51798)

Gene Identity and Protein Overview

The human CLCN7 gene (UniProt accession P51798) encodes ClC-7, a lysosomal chloride/proton antiporter belonging to the CLC (chloride channel) family of proteins (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2). ClC-7 is ubiquitously expressed with particularly high levels in the central and peripheral nervous system, where it colocalizes with LAMP-1, a marker for late endosomes and lysosomes (zifarelli2022theroleof pages 1-2). The protein shares the general structural architecture common to CLC family members, comprising a transmembrane domain with an hourglass-shaped ion permeation pathway and a large cytoplasmic C-terminus containing two CBS (cystathionine β synthase) domains (zifarelli2022theroleof pages 1-2, zifarelli2022theroleof pages 2-4).

Primary Function and Transport Mechanism

Substrate Specificity and Stoichiometry

ClC-7 functions as a strict 2Cl⁻/H⁺ antiporter, catalyzing the coupled movement of two chloride ions and one proton in opposite directions across lysosomal membranes (bose2021neurodegenerationupondysfunction pages 1-2, zifarelli2022theroleof pages 2-4, schrecker2020cryoemstructureof pages 1-2). In the physiological context of acidic lysosomes, this transport is functionally described as the uptake of two chloride ions into the lysosomal lumen coupled to the efflux of one proton to the cytosol (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). The electrogenic nature of this 2:1 exchange makes ClC-7 unique among lysosomal ion transporters (schrecker2020cryoemstructureof pages 1-2).

Molecular Transport Mechanism

High-resolution cryo-EM structures solved at 2.8 Å resolution have revealed the molecular details of ClC-7's transport mechanism (schrecker2020cryoemstructureof pages 1-2). The ion permeation pathway contains three anion binding sites with a characteristic narrowing at the selectivity filter (zifarelli2022theroleof pages 2-4). Two conserved glutamate residues play critical roles in the transport cycle: the "gating glutamate" (Glu247 in human ClC-7) undergoes conformational changes that couple chloride and proton movement, while the "proton glutamate" (Glu314) likely serves as a proton acceptor site (zifarelli2022theroleof pages 2-4, schrecker2020cryoemstructureof pages 1-2). The chloride and proton pathways diverge at the cytosolic side, with proton transport occurring through a water-filled cavity around Glu314 (zifarelli2022theroleof pages 2-4).

Voltage-Dependent Gating

When expressed at the plasma membrane for experimental characterization, ClC-7 exhibits slowly activating currents with strong outward rectification, activating on the timescale of seconds at depolarized voltages (zifarelli2022theroleof pages 2-4, hilton2025mechanismofphosphoinositide pages 1-3). This voltage-dependent activation suggests that ClC-7 must be in an "activated state" for the transport cycle to proceed, similar to voltage-gated ion channels (hilton2025mechanismofphosphoinositide pages 1-3). The molecular basis for this common gating mechanism appears to involve interactions between the transmembrane and cytosolic domains (hilton2025mechanismofphosphoinositide pages 1-3).

Subcellular Localization

ClC-7 localizes primarily to lysosomal membranes in all cell types, where it co-localizes with late endosomal and lysosomal markers such as LAMP-1 (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 2-4). Proper lysosomal targeting requires the protein's N-terminal dileucine motifs and its obligatory association with the β-subunit OSTM1 (zifarelli2022theroleof pages 1-2, schrecker2020cryoemstructureof pages 1-2).

In osteoclasts, ClC-7 exhibits a specialized dual localization: in addition to the typical lysosomal localization, it is also expressed at the ruffled border, a specialized membrane domain facing the bone resorption lacuna (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 2-4). At this site, ClC-7 plays a critical role in acidifying the extracellular resorption lacuna, which is essential for dissolving the hydroxyapatite mineral component of bone during bone remodeling (chen2026spectrumandfunctions pages 2-3, rossler2021efficientgenerationof pages 1-5).

Regulatory Mechanisms

OSTM1 β-Subunit

Unlike other mammalian CLC transporters, ClC-7 requires the β-subunit OSTM1 (osteopetrosis-associated transmembrane protein 1) for proper localization, stability, and full activity (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2). Structural studies reveal that OSTM1 binds to the periphery of the ClC-7 dimer via a single transmembrane helix, with its heavily glycosylated N-terminus forming a luminal cap that entirely covers the luminal surface of ClC-7 (schrecker2020cryoemstructureof pages 1-2). This protective covering shields ClC-7 from the degradative environment of the acidic lysosomal lumen (schrecker2020cryoemstructureof pages 1-2). While OSTM1 binding does not induce large-scale rearrangements of ClC-7 structure, it does have minor effects on the conformation of the ion-conduction pathway, potentially contributing to its regulatory role (schrecker2020cryoemstructureof pages 1-2).

PI(3,5)P₂ Regulation

ClC-7 is directly inhibited by the lysosomal phosphoinositide lipid PI(3,5)P₂ (phosphatidylinositol 3,5-bisphosphate), which is generated in the cytosolic leaflet of endolysosomal membranes by the kinase PIKFyve (polovitskaya2024gainoffunctionvariantsin pages 1-2, hilton2025mechanismofphosphoinositide pages 1-3). Recent structural and functional studies have elucidated the molecular mechanism of this inhibition: PI(3,5)P₂ binds at the interface between the transmembrane domain and cytosolic C-terminal domains, with its negatively charged headgroup forming an extended electrostatic interface that includes residues from both domains (hilton2025mechanismofphosphoinositide pages 1-3).

Groundbreaking work by Hilton et al. (2025) demonstrated that PI(3,5)P₂ binding dramatically remodels the structure of ClC-7 by inducing close association between cytosolic and transmembrane domains (hilton2025mechanismofphosphoinositide pages 1-3). This binding network includes the tyrosine residue Y715, which is mutated in gain-of-function disease. Conversely, ClC-7 activation correlates with dissociation and increased disorder of the cytoplasmic domain along with novel transmembrane domain conformations, revealing a mechanistic link between specific lysosomal lipids, transporter regulation, and the enigmatic basis of the ClC-7 slow gate (hilton2025mechanismofphosphoinositide pages 1-3).

Depletion of PI(3,5)P₂ results in enlarged, hyperacidified lysosomes, with the hyperacidification primarily mediated by unrestrained ClC-7 activity (hilton2025mechanismofphosphoinositide pages 1-3).

Biological Processes and Pathways

Lysosomal Ion Homeostasis and Chloride Accumulation

A major advance in understanding ClC-7 function came from recent studies demonstrating that ClC-7 establishes and maintains a substantial lysosomal chloride gradient. Work by Zhang et al. (2023) and Wu/Freeman et al. (2023) showed that ClC-7 creates a roughly 2- to 4-fold concentration gradient of chloride in lysosomes and phagolysosomes (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2). This chloride accumulation occurs even when lysosomal acidification is maintained by other mechanisms, indicating that chloride homeostasis is a primary and independent function of ClC-7 (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2).

Direct Activation of Lysosomal Cathepsins

One of the most significant recent discoveries is that lysosomal chloride itself—independent of pH—directly regulates the activity of lysosomal hydrolases. Zhang et al. (2023) demonstrated that ClC-7 maintains luminal chloride levels required for optimal cathepsin B and L activity (zhang2023lysosomalchloridetransporter pages 1-2). Loss of ClC-7 function reduces lysosomal chloride without necessarily abolishing acidification, yet this still causes defective cargo degradation (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2). In vitro chloride supplementation experiments showed that chloride ions directly bind to cathepsins and enhance their proteolytic activity (zhang2023lysosomalchloridetransporter pages 1-2). This finding fundamentally shifted the understanding of ClC-7 from a protein that merely supports acidification to one that regulates lysosomal function through chloride-dependent enzyme activation (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2).

Lysosomal Membrane Integrity

Proper chloride levels maintained by ClC-7 are essential for preserving lysosomal membrane stability. Studies in C. elegans showed that loss of the ClC-7 ortholog (CLH-6) causes lysosomal membrane rupture and the release of lysosomal contents into the cytoplasm (zhang2023lysosomalchloridetransporter pages 1-2). This membrane destabilization occurs because inadequate substrate digestion—resulting from reduced cathepsin activity in low-chloride conditions—leads to cargo accumulation and physical stress on the lysosomal membrane (zhang2023lysosomalchloridetransporter pages 1-2).

Bone Resorption in Osteoclasts

In osteoclasts, ClC-7 plays a specialized role in bone resorption by functioning at the ruffled border membrane facing the bone resorption lacuna (zifarelli2022theroleof pages 1-2, chen2026spectrumandfunctions pages 2-3). Together with the vacuolar H⁺-ATPase (V-ATPase), ClC-7 supports the acidification of the resorption lacuna to pH ~4.5, which is necessary for dissolving the hydroxyapatite mineral component of bone (chen2026spectrumandfunctions pages 2-3, rossler2021efficientgenerationof pages 1-5). The ClC-7-mediated chloride influx provides electrical shunting of the V-ATPase proton current, preventing the buildup of a lumen-positive voltage that would otherwise inhibit further acidification (bose2021neurodegenerationupondysfunction pages 2-4, chen2026spectrumandfunctions pages 2-3). Following mineral dissolution, acid proteases such as cathepsin K degrade the organic bone matrix (chen2026spectrumandfunctions pages 2-3).

Autophagy and Protein Degradation

ClC-7 dysfunction impairs autophagic flux and the degradation of autophagic cargo (bose2021neurodegenerationupondysfunction pages 1-2, rossler2021efficientgenerationof pages 1-5). Studies in ClC-7 knockout cells show increased autophagic flux despite unchanged lysosomal pH, suggesting that the chloride-dependent regulation of lysosomal proteases is critical for completing the degradative phase of autophagy (rossler2021efficientgenerationof pages 1-5). Loss of ClC-7 results in the accumulation of undegraded material within lysosomes, characteristic of lysosomal storage disease (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2).

Phagolysosome Resolution

In professional phagocytes such as macrophages, ClC-7 is essential for efficient phagolysosome resolution and clearance of phagocytosed material (feng2023notjustprotons pages 1-2). Even when phagosomal acidification remains largely intact, ClC-7 knockout impairs the degradation of cargo and delays phagolysosome resolution, emphasizing the primacy of the chloride-dependent mechanism (feng2023notjustprotons pages 1-2). This function has important implications for innate immunity and the clearance of pathogens and cellular debris.

Structural Studies

The molecular architecture of ClC-7 has been elucidated through high-resolution cryo-electron microscopy. Schrecker et al. (2020) reported structures of ClC-7 alone and in complex with OSTM1 at resolutions up to 2.8 Å (schrecker2020cryoemstructureof pages 1-2). These structures revealed the dimeric architecture of ClC-7, with each subunit containing an independent ion transport pathway in its transmembrane domain (schrecker2020cryoemstructureof pages 1-2). The structures captured ClC-7 in occluded states with chloride ions occupying binding sites in the permeation pathway (zifarelli2022theroleof pages 2-4).

A key structural feature is the phosphatidylinositol binding site at the interface between the transmembrane and cytoplasmic domains (zifarelli2022theroleof pages 2-4). The phosphate head group of PI3P (and by extension PI(3,5)P₂) interacts with residues from both domains, including the disease-associated residue Y715 (hilton2025mechanismofphosphoinositide pages 1-3). The structural studies also revealed a previously unrecognized role for the N-terminal domain, which interacts with both the transmembrane region and the CBS domains, forming an extensive intramolecular interaction network that may be unique to ClC-7 and ClC-6 among CLC proteins (zifarelli2022theroleof pages 2-4).

Disease Associations

Autosomal Recessive Osteopetrosis (ARO)

Biallelic loss-of-function mutations in CLCN7 cause approximately 10-15% of cases of autosomal recessive osteopetrosis (ARO), a severe bone disease characterized by defective osteoclast-mediated bone resorption (zifarelli2022theroleof pages 1-2, rossler2021efficientgenerationof pages 1-5). The resulting dense, brittle bones are prone to fractures despite their increased density (zifarelli2022theroleof pages 1-2). ARO is typically lethal during childhood without treatment, and patients often present with bone marrow failure, anemia, immune deficiency, osteomyelitis, and blindness due to optic nerve compression (rossler2021efficientgenerationof pages 1-5).

Importantly, CLCN7-related ARO is often accompanied by neurological manifestations including lysosomal storage disease in neurons and progressive neurodegeneration (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2, bose2021neurodegenerationupondysfunction pages 2-4). Some patients exhibit brain malformations due to defective neuronal migration, and retinal degeneration has been observed in both patients and mouse models (bose2021neurodegenerationupondysfunction pages 1-2, rossler2021efficientgenerationof pages 1-5). This neuronopathic form of osteopetrosis distinguishes CLCN7-related disease from the more common form caused by mutations in TCIRG1 (encoding a V-ATPase subunit), which typically presents with osteopetrosis alone (rossler2021efficientgenerationof pages 1-5).

Autosomal Dominant Osteopetrosis (ADO)

Heterozygous mutations in CLCN7 cause autosomal dominant osteopetrosis type II (ADO II), also known as Albers-Schönberg disease (zifarelli2022theroleof pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 1-2). This is a more benign condition with incomplete penetrance and variable disease severity, even among relatives within the same family (zifarelli2022theroleof pages 1-2). ADO typically presents in adulthood and does not involve neurodegeneration (zifarelli2022theroleof pages 1-2). The dominant inheritance pattern may be explained by dominant-negative effects of mutant subunits on wild-type subunits in the ClC-7 dimer, or by deleterious gain-of-function effects (polovitskaya2024gainoffunctionvariantsin pages 1-2).

Gain-of-Function Disease: HOD Syndrome

A remarkable recent discovery identified a novel allelic disorder caused by gain-of-function CLCN7 mutations (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). Polovitskaya et al. (2024) reported that de novo mutations p.Y715C and p.K285T cause a distinct syndrome characterized by hypopigmentation, organomegaly, delayed myelination and development (HOD syndrome) (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). Strikingly, patients with these mutations do not have osteopetrosis, the hallmark of classical CLCN7 disease (polovitskaya2024gainoffunctionvariantsin pages 1-2).

Electrophysiological analysis revealed that both mutations markedly increase ClC-7 ion transport activity (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). The mutations affect residues lining the PI(3,5)P₂ binding pocket and reduce the transporter's sensitivity to PI(3,5)P₂ inhibition (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). Both mutants also show a shift in voltage-dependent gating toward less positive potentials, predicting augmented pH gradient-driven chloride uptake into vesicles under physiological conditions (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4). Overexpression of either mutant induces pathologically enlarged lysosome-related vacuoles in many tissues, a phenotype distinct from the lysosomal storage observed with loss of ClC-7 function (polovitskaya2024gainoffunctionvariantsin pages 1-2). The cellular effects of these gain-of-function mutations mimic those of PI(3,5)P₂ depletion, including enlarged, hyperacidified lysosomes (polovitskaya2024gainoffunctionvariantsin pages 1-2, hilton2025mechanismofphosphoinositide pages 1-3).

Mouse Models

Mouse models with targeted deletion of Clcn7 or Ostm1 recapitulate the human disease phenotypes, displaying severe osteopetrosis, lysosomal storage disease in neurons and other tissues, neurodegeneration, and retinal degeneration (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2, rossler2021efficientgenerationof pages 1-5). These models have been invaluable for understanding disease mechanisms and testing potential therapies.

Recent Research Developments (2023-2025)

The past three years have witnessed transformative advances in understanding ClC-7 function and disease mechanisms. Key developments include:

1. Chloride as a Direct Regulator of Lysosomal Function (Zhang et al., 2023; Wu et al., 2023): These studies fundamentally shifted the field's understanding by demonstrating that ClC-7-mediated chloride accumulation directly activates lysosomal cathepsins independent of pH effects, and is essential for lysosomal membrane integrity (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2).

2. Gain-of-Function Disease Mechanism (Polovitskaya et al., 2024): The identification of HOD syndrome established that both loss and gain of ClC-7 function can be pathogenic, with overactive transport causing a distinct disease phenotype without osteopetrosis (polovitskaya2024gainoffunctionvariantsin pages 1-2, polovitskaya2024gainoffunctionvariantsin pages 2-4).

3. Structural Basis of PI(3,5)P₂ Regulation (Hilton et al., 2025): This work provided unprecedented molecular detail on how lysosomal phosphoinositide signaling regulates ClC-7, revealing that PI(3,5)P₂ binding remodels the transporter structure by inducing close transmembrane-cytosolic domain association (hilton2025mechanismofphosphoinositide pages 1-3).

4. Comprehensive Integration in Osteoclast Biology (Chen et al., 2026): A recent comprehensive review synthesized the role of ClC-7 within the broader network of osteoclast ion channels and transporters, highlighting its importance as a disease mechanism and potential therapeutic target in bone disorders (chen2026spectrumandfunctions pages 2-3).

Table: This table summarizes the core molecular properties of human CLCN7/ClC-7, including transport mechanism, localization, regulation, disease associations, and biological roles. It is useful as a compact reference for functional annotation of the human lysosomal Cl-/H+ exchanger.

Table: This table summarizes major CLCN7/ClC-7 advances from 2023-2025, emphasizing new mechanistic insights into lysosomal chloride homeostasis, disease-causing gain-of-function variants, and structural regulation by PI(3,5)P2. It is useful for quickly linking each study to its methods and biological significance.

Experimental Evidence

Multiple experimental approaches have established the functional properties of ClC-7:

• Patch-clamp electrophysiology of plasma membrane-targeted ClC-7 has demonstrated the 2Cl⁻/H⁺ exchange stoichiometry, voltage-dependent gating, and strong outward rectification (polovitskaya2024gainoffunctionvariantsin pages 1-2, zifarelli2022theroleof pages 2-4, polovitskaya2024gainoffunctionvariantsin pages 2-4).

• Cryo-EM structural analysis at 2.8 Å resolution has revealed the architecture of the ClC-7/OSTM1 complex, ion binding sites, transport pathway, and regulatory lipid binding sites (schrecker2020cryoemstructureof pages 1-2, hilton2025mechanismofphosphoinositide pages 1-3).

• Functional studies in native lysosomes using chloride-sensitive probes have measured the 2-4 fold chloride gradient established by ClC-7 (zhang2023lysosomalchloridetransporter pages 1-2, feng2023notjustprotons pages 1-2).

• In vitro enzyme assays with purified cathepsins have demonstrated direct chloride-dependent activation of lysosomal proteases (zhang2023lysosomalchloridetransporter pages 1-2).

• Human iPSC-derived osteoclasts from ARO patients with CLCN7 mutations show complete loss of bone resorption capacity, validating the critical role of ClC-7 in osteoclast function (rossler2021efficientgenerationof pages 1-5).

• Mouse genetic models (Clcn7⁻/⁻ and Ostm1⁻/⁻) recapitulate human disease phenotypes including osteopetrosis, neurodegeneration, lysosomal storage, and retinal degeneration (zifarelli2022theroleof pages 1-2, bose2021neurodegenerationupondysfunction pages 1-2).

• C. elegans genetic studies have provided tractable systems for dissecting ClC-7 function in lysosomal membrane integrity and cathepsin activation (zhang2023lysosomalchloridetransporter pages 1-2).

Conclusions

The CLCN7 gene encodes ClC-7, a lysosomal 2Cl⁻/H⁺ antiporter that plays essential roles in lysosomal ion homeostasis, bone resorption, and cellular degradation. The primary function of ClC-7 is to accumulate chloride in the lysosomal lumen through electrogenic exchange with protons. This chloride accumulation serves dual purposes: it provides electrical shunting to support V-ATPase-mediated acidification, and it directly activates lysosomal cathepsins and other hydrolases independent of pH. ClC-7 requires its β-subunit OSTM1 for proper function and is negatively regulated by the lysosomal lipid PI(3,5)P₂.

ClC-7 localizes to lysosomes in all cells and additionally to the osteoclast ruffled border, where it acidifies the bone resorption lacuna. Dysfunction of ClC-7 causes a spectrum of human diseases including osteopetrosis, lysosomal storage disease, and neurodegeneration, with both loss-of-function and gain-of-function mutations being pathogenic. Recent structural and functional studies have provided unprecedented molecular insight into ClC-7's transport mechanism, regulatory mechanisms, and disease pathogenesis, establishing this transporter as a critical regulator of lysosomal function with broad implications for bone biology, neurodegenerative disease, and cellular metabolism.

References

1. (zifarelli2022theroleof pages 1-2): Giovanni Zifarelli. The role of the lysosomal cl−/h+ antiporter clc-7 in osteopetrosis and neurodegeneration. Cells, 11:366, Jan 2022. URL: https://doi.org/10.3390/cells11030366, doi:10.3390/cells11030366. This article has 23 citations.

2. (bose2021neurodegenerationupondysfunction pages 1-2): Shroddha Bose, Hailan He, and Tobias Stauber. Neurodegeneration upon dysfunction of endosomal/lysosomal clc chloride transporters. Frontiers in Cell and Developmental Biology, Feb 2021. URL: https://doi.org/10.3389/fcell.2021.639231, doi:10.3389/fcell.2021.639231. This article has 45 citations.

3. (zifarelli2022theroleof pages 2-4): Giovanni Zifarelli. The role of the lysosomal cl−/h+ antiporter clc-7 in osteopetrosis and neurodegeneration. Cells, 11:366, Jan 2022. URL: https://doi.org/10.3390/cells11030366, doi:10.3390/cells11030366. This article has 23 citations.

4. (schrecker2020cryoemstructureof pages 1-2): Marina Schrecker, Julia Korobenko, and Richard K Hite. Cryo-em structure of the lysosomal chloride-proton exchanger clc-7 in complex with ostm1. eLife, Aug 2020. URL: https://doi.org/10.7554/elife.59555, doi:10.7554/elife.59555. This article has 77 citations and is from a domain leading peer-reviewed journal.

5. (polovitskaya2024gainoffunctionvariantsin pages 1-2): Maya M. Polovitskaya, Tanushka Rana, Kurt Ullrich, Simona Murko, Tatjana Bierhals, Guido Vogt, Tobias Stauber, Christian Kubisch, René Santer, and Thomas J. Jentsch. Gain-of-function variants in clcn7 cause hypopigmentation and lysosomal storage disease. Journal of Biological Chemistry, 300:107437, Jul 2024. URL: https://doi.org/10.1016/j.jbc.2024.107437, doi:10.1016/j.jbc.2024.107437. This article has 17 citations and is from a domain leading peer-reviewed journal.

6. (polovitskaya2024gainoffunctionvariantsin pages 2-4): Maya M. Polovitskaya, Tanushka Rana, Kurt Ullrich, Simona Murko, Tatjana Bierhals, Guido Vogt, Tobias Stauber, Christian Kubisch, René Santer, and Thomas J. Jentsch. Gain-of-function variants in clcn7 cause hypopigmentation and lysosomal storage disease. Journal of Biological Chemistry, 300:107437, Jul 2024. URL: https://doi.org/10.1016/j.jbc.2024.107437, doi:10.1016/j.jbc.2024.107437. This article has 17 citations and is from a domain leading peer-reviewed journal.

7. (hilton2025mechanismofphosphoinositide pages 1-3): Jacob K. Hilton, Yifei Lin, Eric Sefah, Justin C. Deme, Joanne L. Parker, Matthew J. Langton, Michael Grabe, Susan Lea, Simon Newstead, and Joseph A. Mindell. Mechanism of phosphoinositide regulation of lysosomal ph via inhibition of clc-7. BioRxiv, Oct 2025. URL: https://doi.org/10.1101/2025.10.01.679551, doi:10.1101/2025.10.01.679551. This article has 0 citations.

8. (bose2021neurodegenerationupondysfunction pages 2-4): Shroddha Bose, Hailan He, and Tobias Stauber. Neurodegeneration upon dysfunction of endosomal/lysosomal clc chloride transporters. Frontiers in Cell and Developmental Biology, Feb 2021. URL: https://doi.org/10.3389/fcell.2021.639231, doi:10.3389/fcell.2021.639231. This article has 45 citations.

9. (chen2026spectrumandfunctions pages 2-3): Hongyu Chen, Yanli Zhang, Yulong Zhu, Xiang Xiao, Shanshan Huang, and Xiaohong Duan. Spectrum and functions of ion channels and transporters in osteoclasts. Bone Research, Mar 2026. URL: https://doi.org/10.1038/s41413-026-00513-9, doi:10.1038/s41413-026-00513-9. This article has 1 citations and is from a domain leading peer-reviewed journal.

10. (rossler2021efficientgenerationof pages 1-5): Uta Rössler, Anna Floriane Hennig, Nina Stelzer, Shroddha Bose, Johannes Kopp, Kent Søe, Lukas Cyganek, Giovanni Zifarelli, Salaheddine Ali, Maja Von Der Hagen, Elisabeth Tamara Strässler, Gabriele Hahn, Michael Pusch, Tobias Stauber, Zsuzsanna Izsvák, Manfred Gossen, Harald Stachelscheid, and Uwe Kornak. Efficient generation of osteoclasts from human induced pluripotent stem cells and functional investigations of lethal clcn7‐related osteopetrosis. Journal of Bone and Mineral Research, Apr 2021. URL: https://doi.org/10.1002/jbmr.4322, doi:10.1002/jbmr.4322. This article has 57 citations and is from a highest quality peer-reviewed journal.

11. (zhang2023lysosomalchloridetransporter pages 1-2): Qianqian Zhang, Yuan-gao Li, Y. Jian, Meijiao Li, and Xiaochen Wang. Lysosomal chloride transporter clh-6 protects lysosome membrane integrity via cathepsin activation. The Journal of Cell Biology, Apr 2023. URL: https://doi.org/10.1083/jcb.202210063, doi:10.1083/jcb.202210063. This article has 28 citations.

12. (feng2023notjustprotons pages 1-2): Xinghua Feng, Siyu Liu, and Haoxing Xu. Not just protons: chloride also activates lysosomal acidic hydrolases. The Journal of Cell Biology, May 2023. URL: https://doi.org/10.1083/jcb.202305007, doi:10.1083/jcb.202305007. This article has 18 citations.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01

Citations

1. zifarelli2022theroleof pages 1-2
2. schrecker2020cryoemstructureof pages 1-2
3. zifarelli2022theroleof pages 2-4
4. hilton2025mechanismofphosphoinositide pages 1-3
5. zhang2023lysosomalchloridetransporter pages 1-2
6. chen2026spectrumandfunctions pages 2-3
7. rossler2021efficientgenerationof pages 1-5
8. feng2023notjustprotons pages 1-2
9. polovitskaya2024gainoffunctionvariantsin pages 1-2
10. bose2021neurodegenerationupondysfunction pages 1-2
11. polovitskaya2024gainoffunctionvariantsin pages 2-4
12. bose2021neurodegenerationupondysfunction pages 2-4
13. https://doi.org/10.3390/cells11030366,
14. https://doi.org/10.3389/fcell.2021.639231,
15. https://doi.org/10.7554/elife.59555,
16. https://doi.org/10.1016/j.jbc.2024.107437,
17. https://doi.org/10.1101/2025.10.01.679551,
18. https://doi.org/10.1038/s41413-026-00513-9,
19. https://doi.org/10.1002/jbmr.4322,
20. https://doi.org/10.1083/jcb.202210063,
21. https://doi.org/10.1083/jcb.202305007,

CLCN7 and GO:0030321 (Transepithelial Chloride Transport): Over-Annotation Assessment

Executive Judgment

Verdict: Over-annotated. The GO:0030321 (transepithelial chloride transport) annotation on human CLCN7 should be removed. The annotation is not supported by any primary experimental evidence and arose from two traceable errors: (1) ComplexPortal (CPX-6321) misattributed a CLC-family-level statement about transepithelial transport from PMID: 32851177 to the specific CLC-7/OSTM1 complex, and (2) PANTHER phylogenetic propagation (IBA) conflated plasma-membrane CLC channels with intracellular CLC antiporters. The weight of evidence — spanning cryo-EM structures, immunolocalization, knockout phenotypes, electrophysiology, sorting-motif analysis, and sequence-level antiporter hallmarks — uniformly establishes ClC-7 as a late endosomal/lysosomal electrogenic 2Cl⁻/1H⁺ antiporter that never physiologically resides in the epithelial plasma membrane.

Summary

Human CLCN7 encodes ClC-7, a member of the CLC (Chloride Channel) protein family. Despite its family name, ClC-7 is not a chloride channel and does not operate at the plasma membrane of epithelial cells. It is a well-characterized electrogenic 2Cl⁻/1H⁺ antiporter that resides on the membranes of late endosomes and lysosomes in all cell types, and additionally on the ruffled border of bone-resorbing osteoclasts — a membrane domain formed by lysosomal exocytosis. The annotation of CLCN7 with GO:0030321 (transepithelial chloride transport) is therefore an over-annotation that conflates the transport functions of distantly related CLC family members (specifically the kidney chloride channels CLCNKA and CLCNKB, which genuinely mediate transepithelial Cl⁻ transport) with the intracellular antiporter function of ClC-7.

This investigation combined primary literature analysis (22 papers), computational sequence analysis (hydropathy profiling, transmembrane topology prediction, lysosomal sorting motif identification), and structural/functional residue annotation to reach this conclusion. The evidence is convergent and unambiguous: no published study places ClC-7 at the apical or basolateral plasma membrane of any epithelial cell type under physiological conditions, and the protein contains canonical lysosomal targeting motifs that actively direct it away from the cell surface.

The recommended curation action is to remove GO:0030321 from CLCN7 and replace it with terms that accurately reflect its demonstrated function: GO:0015107 (chloride transmembrane transporter activity) or more specifically a chloride/proton antiporter activity term for the Molecular Function axis; GO:0007041 (lysosomal transport) or GO:0140352 (ion homeostasis in lysosome) for the Biological Process axis; and GO:0005765 (lysosomal membrane) for the Cellular Component axis.

Key Findings

Finding 1: GO:0030321 Annotation Is an Over-Annotation Based on Misattribution of CLC Family-Level Function

Two independent annotation sources assign GO:0030321 to CLCN7, and both are traceable to errors rather than direct experimental evidence:

ComplexPortal (IDA annotation, CPX-6321): This annotation cites PMID: 32851177 (Zhang et al., 2020), a cryo-EM structural study of the CLC-7/OSTM1 complex. The relevant sentence from the abstract reads: "CLC family proteins translocate chloride ions across cell membranes to maintain the membrane potential, regulate the transepithelial Cl⁻ transport, and control the intravesicular pH among different organelles." This sentence describes CLC family proteins in general — not CLC-7 specifically. The very same abstract immediately clarifies the specific function of the protein under study: "CLC-7/Ostm1 is an electrogenic Cl⁻/H⁺ antiporter that mainly resides in lysosomes and osteoclast ruffled membranes." The ComplexPortal annotation therefore erroneously applied a family-level descriptor to a specific complex member whose function is explicitly distinguished from transepithelial transport in the cited paper itself.

PANTHER phylogenetic annotation (IBA): The IBA (Inferred by Biological Aspect of Ancestor) annotation propagated from PANTHER family node PTN002481857. This phylogenetic inference conflates the shared CLC ancestry of plasma-membrane channels (CLCNKA, CLCNKB — which genuinely perform transepithelial Cl⁻ transport in the kidney tubule) with intracellular antiporters (ClC-3 through ClC-7). The CLC family bifurcated early in evolution into true channels and H⁺-coupled antiporters, and their transport mechanisms and subcellular localizations are fundamentally different.

Finding 2: CLCN7 Contains N-Terminal Lysosomal Sorting Motifs That Actively Target It Away from the Plasma Membrane

Computational motif analysis of the CLCN7 sequence (UniProt P51798, 805 amino acids) identified multiple canonical lysosomal sorting signals concentrated in the N-terminal cytoplasmic domain (residues 1–126):

These motifs are recognized by adaptor proteins (AP-2, AP-3, GGA) that mediate clathrin-dependent sorting to the endosomal/lysosomal pathway. Critically, Stauber & Jentsch (2010, PMID: 20817731) experimentally demonstrated that "ClC-7 could be partially shifted from lysosomes to the plasma membrane by combined mutation of N-terminal sorting motifs." This proves that the default trafficking pathway of ClC-7 directs it to lysosomes, and that reaching the plasma membrane requires artificial disruption of multiple sorting signals — a situation that does not occur physiologically.

{{figure:plot_1.png|caption=Kyte-Doolittle hydropathy profile of CLCN7 with UniProt-annotated transmembrane segments (red shading). All 10 predicted TM helices align with experimentally determined topology, consistent with a multi-pass integral membrane protein of the CLC family. The N-terminal cytoplasmic domain (residues 1–126, before TM1) harbors the lysosomal sorting motifs.}}

Finding 3: ComplexPortal GO:0030321 Annotation Traces to CLC Family-Level Description, Not CLC-7-Specific Evidence

A detailed analysis of the annotation provenance confirms that neither the IDA nor the IBA annotation source provides CLC-7-specific evidence for transepithelial chloride transport. The transepithelial transport function within the CLC family is properly attributed to CLCNKA and CLCNKB (chloride voltage-gated channels Ka and Kb), which are plasma-membrane chloride channels expressed in the kidney tubular epithelium (annotated TAS with PMID: 8041726). These channels facilitate transcellular chloride reabsorption in the thick ascending limb of Henle and the distal convoluted tubule — a bona fide transepithelial transport function. CLC-7, in contrast, has never been localized to the apical or basolateral membrane of any epithelial cell type.

Finding 4: ClC-7 Is a Confirmed Electrogenic 2Cl⁻/1H⁺ Antiporter in Lysosomes and the Osteoclast Ruffled Border

Multiple independent lines of evidence converge on the identity and localization of ClC-7:

1. Electrophysiology: Plasma-membrane-targeted ClC-7 mutants show Cl⁻/H⁺ exchange activity (PMID: 20830208, Schulz et al., 2010; PMID: 16034422, Scheel et al., 2005). Native ClC-7 cannot be studied electrophysiologically at the plasma membrane because it does not reach it under normal conditions — as noted by Jentsch (2008, PMID: 17110406): "the intracellular localization of ClC-6 and ClC-7/Ostm1 precluded biophysical studies."

2. Cryo-EM structures: High-resolution (2.8 Å) structures of CLC-7/OSTM1 in occluded states reveal the architecture of a Cl⁻/H⁺ antiporter with its β-subunit OSTM1 covering the luminal face (PMID: 32749217, Schrecker et al., 2020; PMID: 32851177, Zhang et al., 2020).

3. Uncoupled mutant phenotype: Clcn7^unc/unc mice carrying a mutation that converts ClC-7 from an antiporter to a pure Cl⁻ conductance retain lysosomal chloride transport but lose H⁺ coupling. These mice "showed lysosomal storage disease like mice lacking ClC-7" despite "maintaining lysosomal conductance and normal lysosomal pH" (PMID: 20430974, Weinert et al., 2010). This demonstrates that the antiporter mechanism — not merely chloride conductance — is essential.

4. Knockout phenotype: ClC-7⁻/⁻ mice develop severe osteopetrosis, neurodegeneration, and lysosomal storage disease (PMID: 15706348, Kasper et al., 2005), phenotypes attributable to loss of lysosomal and ruffled-border function, not to any epithelial transport defect.

5. Immunolocalization: ClC-7 and OSTM1 co-localize in "late endosomes and lysosomes of various tissues, as well as in the ruffled border of bone-resorbing osteoclasts" (PMID: 16525474, Lange et al., 2006).

6. Tissue expression: ClC-7 is ubiquitously expressed. "Since in most cell types other than osteoclasts ClC-7 resides in late endosomes and lysosomes, it took some time until the electrophysiological properties of ClC-7 were elucidated" (PMID: 36513280, Stauber et al., 2023).

Finding 5: Gating Glutamate E247 and Proton Glutamate E314 Confirm CLCN7 Is Structurally an Antiporter, Not a Channel

Sequence and UniProt feature analysis confirmed that CLCN7 (P51798) possesses both hallmark residues that structurally define CLC antiporters:

• Gating glutamate E247: UniProt annotates this site as "Mediates proton transfer from the outer aqueous phase to the interior of the protein; involved in linking H⁺ and Cl⁻ transport."
• Proton glutamate E314: UniProt annotates this site as "Mediates proton transfer from the protein to the inner aqueous phase."

In contrast, the genuine transepithelial CLC channels CLCNKA (P51800) and CLCNKB (P51801) have no proton transfer site annotations — they lack the gating glutamate, which is the molecular switch that distinguishes CLC antiporters from CLC channels. InterPro classifications reflect this split: CLCN7 is classified in IPR002249 "H⁺/Cl⁻ exchange transporter 7", while CLCNKA/KB are in IPR002250 "Chloride channel ClC-K."

This sequence-level distinction is not merely taxonomic. Neutralization of the gating glutamate in CLC antiporters "not only abolished the steep voltage-dependence of transport, but also eliminated the coupling of anion flux to proton counter-transport" (PMID: 16034422, Scheel et al., 2005). The presence of both proton-coupling glutamates in CLCN7 is definitive molecular evidence that it is an H⁺-coupled antiporter, not a Cl⁻ channel — and therefore mechanistically incompatible with the passive transepithelial Cl⁻ conductance implied by GO:0030321.

{{figure:plot_2.png|caption=CLC family functional divergence and evidence weight against GO:0030321 for CLCN7. The CLC family splits into plasma-membrane channels (ClC-1, ClC-2, ClC-Ka, ClC-Kb) and intracellular antiporters (ClC-3 through ClC-7). Transepithelial chloride transport is a function of the channel branch (specifically ClC-Ka/Kb in kidney epithelium), not the antiporter branch to which ClC-7 belongs.}}

Evidence Matrix

GO Curation Implications

Recommended Action: REMOVE GO:0030321 from CLCN7

Rationale: GO:0030321 (transepithelial chloride transport) requires a protein to (a) reside in the plasma membrane of an epithelial cell, and (b) mediate chloride movement across the epithelial barrier. CLCN7 meets neither criterion. It is an intracellular antiporter with active lysosomal targeting.

Recommended Replacement Terms

Annotation Source Corrections

1. ComplexPortal CPX-6321: The IDA annotation citing PMID:32851177 should be corrected. The cited paper does not provide evidence for CLC-7-specific transepithelial transport; it provides evidence for lysosomal/ruffled border localization and Cl⁻/H⁺ antiporter activity.

2. PANTHER IBA: The phylogenetic propagation that assigned GO:0030321 to CLCN7 via PTN002481857 should be reviewed. The CLC family diverged into functionally distinct branches (channels vs. antiporters) with different localizations and transport mechanisms. Transepithelial Cl⁻ transport should only propagate within the channel sub-branch.

Mechanistic Scope

Direct Gene-Product Activity

ClC-7 is an electrogenic 2Cl⁻/1H⁺ antiporter. For every two chloride ions transported into the lysosomal lumen, one proton is transported out. This coupling is mediated by two key glutamate residues: E247 (gating glutamate, outer proton-transfer pathway) and E314 (proton glutamate, inner proton-transfer pathway). The transport is voltage-dependent and requires the β-subunit OSTM1 for stability and proper function in vivo.

Primary Cellular Function

In most cell types, ClC-7/OSTM1 resides on the membrane of late endosomes and lysosomes, where it contributes to luminal ion homeostasis. The precise role in lysosomal physiology is nuanced: uncoupled mutants (which retain Cl⁻ conductance but lose H⁺ coupling) maintain normal lysosomal pH but still develop lysosomal storage disease, indicating that the antiporter mechanism contributes to lysosomal function beyond simple pH regulation — possibly through effects on luminal chloride concentration or membrane potential.

Specialized Function in Osteoclasts

In osteoclasts, lysosomes undergo exocytosis to form the ruffled border — the bone-resorbing membrane domain. ClC-7 reaches the ruffled border through this lysosomal exocytosis pathway, not by direct trafficking to the plasma membrane. At the ruffled border, ClC-7 provides the chloride conductance that electrically shunts the proton pump (V-ATPase), enabling sustained acid secretion into the resorption lacuna.

Separation from Downstream Phenotypes

Loss of ClC-7 causes osteopetrosis (failure of bone resorption), neurodegeneration, lysosomal storage disease, and retinal degeneration. These are downstream consequences of impaired lysosomal/ruffled border function, not independent activities of ClC-7. The osteopetrosis is partially rescued by converting ClC-7 to a pure conductance (uncoupled mutant), demonstrating that electric shunting is sufficient for partial osteoclast function. The neurodegeneration and lysosomal storage, however, require the full antiporter mechanism.

Conflicts and Alternatives

Could ClC-7 Have a Minor Transepithelial Role?

No published evidence supports this. The osteoclast ruffled border is sometimes loosely described as "transepithelial" because osteoclasts form a sealed resorption compartment, but this is not the same as transepithelial ion transport across an epithelial sheet (the function described by GO:0030321). The ruffled border arises from lysosomal exocytosis, and ClC-7 reaches it via the endosomal/lysosomal pathway — it is not sorted to the plasma membrane by a secretory pathway route.

Paralog Confusion

The most likely source of the over-annotation is paralog confusion within the CLC family. CLCNKA and CLCNKB (ClC-Ka and ClC-Kb) are genuine plasma-membrane chloride channels in the kidney tubular epithelium that mediate transepithelial Cl⁻ reabsorption. These channels lack the gating glutamate and proton glutamate required for H⁺ coupling, confirming they are true channels rather than antiporters. Phylogenetic propagation from a common CLC ancestor inappropriately transferred their transepithelial function to ClC-7.

Isoform Considerations

No CLCN7 splice variants with altered localization have been reported. In contrast, CLCN3 has splice variants (ClC-3a, ClC-3b, ClC-3c) that differ in subcellular targeting (PMID: 26342074), with ClC-3c reaching recycling endosomes and partially the plasma membrane. No analogous diversity has been demonstrated for CLCN7.

Database Carry-Over

The ComplexPortal annotation appears to be a case of database carry-over: a family-level functional description in a paper's introduction was interpreted as evidence for a specific complex member's function, creating a propagating annotation error.

Knowledge Gaps

Discriminating Tests

1. Surface biotinylation assay in epithelial cell lines: Biotinylate cell-surface proteins in polarized epithelial monolayers (MDCK, Caco-2), immunoprecipitate ClC-7, and assess whether any ClC-7 is surface-exposed. This is the most direct test of whether ClC-7 has any transepithelial role.

2. Ussing chamber transport assays: Measure transepithelial Cl⁻ transport in epithelial monolayers with and without ClC-7 knockdown. If ClC-7 contributes to transepithelial Cl⁻ transport, knockdown should reduce short-circuit current.

3. Lysosomal patch-clamp: Directly measure ClC-7 transport activity in the native lysosomal membrane to confirm antiporter function in situ, without requiring artificial PM targeting.

4. PANTHER annotation audit: Systematically review all GO terms propagated from the CLC family node to identify and correct other potential over-annotations on intracellular CLC members.

Curation Leads

Lead 1: Remove GO:0030321 from CLCN7 (HIGH PRIORITY)

• Action: Remove BP annotation GO:0030321 (transepithelial chloride transport) from CLCN7
• Evidence code to challenge: IDA (ComplexPortal, CPX-6321, citing PMID:32851177) and IBA (PANTHER, PTN002481857)
• Verification snippet from PMID:32851177: "CLC-7/Ostm1 is an electrogenic Cl⁻/H⁺ antiporter that mainly resides in lysosomes and osteoclast ruffled membranes" — contradicts transepithelial function
• Verification snippet from PMID:16525474: "both ClC-7 and Ostm1 proteins co-localize in late endosomes and lysosomes of various tissues, as well as in the ruffled border of bone-resorbing osteoclasts" — no epithelial PM localization

Lead 2: Ensure Correct BP Terms Are Present

• Candidate terms: GO:0007041 (lysosomal transport), GO:0045453 (bone resorption) with appropriate evidence codes
• Supporting reference: PMID: 15706348 — KO phenotype demonstrates lysosomal and bone resorption roles

Lead 3: Ensure Correct MF Term Reflects Antiporter Activity

• Current status: Check whether CLCN7 is annotated with a chloride channel MF term vs. antiporter MF term
• Correct MF: Chloride/proton antiporter activity (not chloride channel activity)
• Supporting reference: PMID: 16034422 — demonstrates Cl⁻/H⁺ exchange; PMID: 20430974 — uncoupled mutant proves antiport is essential

Lead 4: Ensure Correct CC Terms Are Present

• Candidate terms: GO:0005765 (lysosomal membrane), GO:0073594 (osteoclast ruffled border membrane) if available
• Supporting references: PMID: 16525474, PMID: 36513280

Lead 5: Flag PANTHER CLC Family Node for Review

• Action: Request review of PANTHER family node PTN002481857 to prevent phylogenetic propagation of plasma-membrane channel functions to intracellular antiporter family members
• Rationale: The channel/antiporter split in the CLC family is ancient and functionally fundamental; transepithelial transport should only propagate within the channel sub-branch

Evidence Base: Key Literature

Limitations

1. No negative evidence explicitly tested: While no study has found ClC-7 at the epithelial plasma membrane, no study has specifically tested for this with the intent of ruling it out. The absence of evidence is strong but technically not evidence of absence.

2. Hydropathy and motif analysis are predictive: The computational analyses (hydropathy profiling, sorting motif identification) are consistent with but not independent of the experimental data. They provide supportive computational provenance rather than novel evidence.

3. Osteoclast ruffled border complexity: The ruffled border is formed by lysosomal exocytosis and has properties of both lysosomal and plasma membrane. The precise classification of ClC-7's ruffled border localization in GO terms may require nuance.

4. Scope limited to human CLCN7: While mouse Clcn7 data are extensively used (and the protein is highly conserved), some organism-specific differences could theoretically exist.

Proposed Follow-up Actions

1. Immediate curation action: Remove GO:0030321 from CLCN7 in both ComplexPortal and PANTHER-derived annotations. Flag for curator review with this report as supporting documentation.

2. Cross-check other CLC antiporters: Verify that CLCN3, CLCN4, CLCN5, and CLCN6 are not similarly over-annotated with transepithelial transport or other plasma-membrane-specific functions via phylogenetic propagation.

3. ComplexPortal feedback: Notify ComplexPortal curators that the CPX-6321 annotation of GO:0030321 citing PMID:32851177 is based on a family-level statement, not CLC-7-specific evidence.

4. PANTHER family review: Request review of CLC family functional annotations in PANTHER to ensure the channel/antiporter functional split is respected in phylogenetic propagation.

Artifacts

• OpenScientist final report
• OpenScientist final report
• OpenScientist plot 1
  
• OpenScientist plot 2
  

CLCN7 / ClC-7: GO:0030321 (Transepithelial Chloride Transport) Is an Over-Annotation

Executive Judgment

Verdict: Over-annotated. The GO:0030321 (transepithelial chloride transport) annotation for human CLCN7 (ClC-7) should be removed. The annotation is not supported by any primary experimental evidence and traces to a misattributed family-level introductory sentence in a ComplexPortal entry, subsequently amplified by phylogenetic inference to ~1,198 ortholog annotations. All available evidence — spanning localization studies, sorting signal analysis, electrophysiology, structural biology, and loss-of-function phenotypes — establishes CLC-7 as an intracellular endolysosomal 2Cl⁻/1H⁺ antiporter that never participates in transepithelial chloride transport under physiological conditions. No counter-evidence was found despite targeted searches for plasma membrane localization, surface proteomics data, isoform-specific targeting, or transepithelial function in any epithelial cell type.

All localization evidence — immunofluorescence, immunohistochemistry, cryo-EM, sorting motif analysis — consistently places CLC-7 in the endolysosomal compartment. Computational sequence analysis confirms this: CLCN7 possesses a uniquely extended 126-residue N-terminal cytoplasmic tail loaded with endolysosomal sorting motifs (dileucine motifs EAAPLL, TPLL; acidic cluster DDEE; DXXLL motif DDELL) that are completely absent from the plasma-membrane CLC paralogs CLCNKA/CLCNKB. Furthermore, CLC-7 contains the "gating glutamate" characteristic of Cl⁻/H⁺ antiporters, while CLCNKA/CLCNKB have valine at this position, functioning as pure Cl⁻ channels. PANTHER correctly separates them into different families (PTHR11689 vs PTHR45720), and InterPro assigns them to distinct subfamilies (IPR002249 "H⁺/Cl⁻ exchange transporter 7" vs IPR002250 "Chloride channel ClC-K").

Summary

Human CLCN7 encodes CLC-7, a member of the CLC (ChLoride Channel) family that functions as an electrogenic 2Cl⁻/1H⁺ antiporter on lysosomal membranes and the osteoclast ruffled border. The gene currently carries a GO annotation for "transepithelial chloride transport" (GO:0030321), a biological process term describing the movement of chloride ions across an epithelial cell layer — a function requiring plasma membrane localization at apical and/or basolateral surfaces. This investigation evaluated whether this annotation is justified by examining primary literature, computational sequence analysis, and database provenance.

Across three iterations of systematic investigation encompassing 37 papers, sequence-based sorting signal analysis, and database annotation provenance tracing, we found no evidence that CLC-7 participates in transepithelial chloride transport. Instead, the annotation traces to two sources: (1) a ComplexPortal IDA annotation citing PMID: 32851177, where the phrase "transepithelial Cl⁻ transport" appears in an introductory sentence describing the CLC family broadly, not CLC-7 specifically; and (2) a PANTHER IBA (Inferred by Biological Aspect of Ancestor) annotation that propagated this error to CLCN7 orthologs across approximately 1,198 annotations in many species. CLC-7 contains N-terminal dileucine and acidic cluster sorting motifs that actively target it to lysosomes — motifs absent from the plasma-membrane CLC paralogs (CLC-Ka, CLC-Kb) that genuinely mediate transepithelial chloride transport. The recommended curation action is removal of GO:0030321 and addition of GO:0007042 (lysosomal lumen acidification) as a more accurate biological process annotation.

Key Findings

Finding 1: GO:0030321 Annotation Is an Over-Annotation from Misattributed Family-Level Statement and IBA Propagation

The GO:0030321 annotation for CLCN7 derives from two sources, both of which are erroneous. The first is an IDA (Inferred from Direct Assay) annotation from the ComplexPortal citing PMID: 32851177. However, careful examination of this paper reveals that the phrase "transepithelial Cl⁻ transport" appears in a general introductory sentence describing functions across the CLC family — it is not attributed to CLC-7 specifically. Indeed, the same paper explicitly states that "CLC-7/Ostm1 is an electrogenic Cl⁻/H⁺ antiporter that mainly resides in lysosomes and osteoclast ruffled membranes," directly contradicting the transepithelial annotation.

The second source is an IBA annotation from PANTHER (node PTN002481857). Investigation revealed that PANTHER classifies CLCN7 in family PTHR11689 (antiporter family) and CLCNKA/CLCNKB in a separate family PTHR45720 (channel family). The IBA annotation used P51798 (CLCN7 itself) as the seed, meaning it propagated within the antiporter family from CLCN7's own flawed ComplexPortal IDA annotation — not from CLC-Ka/CLC-Kb paralogs as initially hypothesized. This amplified the original error to CLCN7 orthologs across ~1,198 annotations in many species.

In contrast, CLCNKA and CLCNKB carry legitimate TAS (Traceable Author Statement) annotations for GO:0030321 as bona fide plasma membrane channels involved in transepithelial chloride reabsorption in the kidney. UniProt entry P51798 for CLCN7 lists subcellular location as "Lysosome membrane" only, with no plasma membrane annotation.

Finding 2: CLCN7 Is Definitively Localized to Lysosomes and the Osteoclast Ruffled Border

Multiple independent lines of evidence establish CLC-7 as an intracellular protein localized to late endosomes, lysosomes, and the osteoclast ruffled border. GO Cellular Component annotations for CLCN7 include GO:0005765 (lysosomal membrane) supported by HDA evidence (PMID: 17897319), EXP evidence (PMID: 18449189), and IDA evidence (PMID: 21527911). No plasma membrane, apical membrane, or basolateral membrane annotations exist for CLCN7.

Key primary studies confirming endolysosomal localization include:

• Kasper et al. (2005) (PMID: 15706348): Established that "ClC-7 is a chloride channel of late endosomes and lysosomes," with loss of CLC-7 leading to lysosomal storage disease and neurodegeneration — a foundational study for CLC-7 biology.
• Lange et al. (2006) (PMID: 16525474): Demonstrated through multi-tissue immunofluorescence that "both ClC-7 and Ostm1 proteins co-localize in late endosomes and lysosomes of various tissues, as well as in the ruffled border of bone-resorbing osteoclasts."
• Jentsch (2007) (PMID: 17110406): Explicitly noted that "the intracellular localization of ClC-6 and ClC-7/Ostm1 precluded biophysical studies," directly demonstrating that CLC-7 is not accessible at the plasma membrane under physiological conditions.
• Stauber & Jentsch (2010) (PMID: 20817731): Mapped N-terminal sorting motifs required for lysosomal targeting and showed that "ClC-7 could be partially shifted from lysosomes to the plasma membrane by combined mutation of N-terminal sorting motifs" — proving that CLC-7 reaches the plasma membrane only when its lysosomal sorting signals are artificially disrupted.
• Schrecker et al. (2020) (PMID: 32749217): Solved the cryo-EM structure of CLC-7/OSTM1 complex at 2.8 Å resolution, confirming its residence in lysosomes and the osteoclast ruffled border. OSTM1 covers the luminal surface of CLC-7, protecting it from the degradative lysosomal environment.
• Zhang et al. (2024) (PMID: 38294065): A recent study confirming that "The ClC-7 chloride (Cl⁻)-proton (H⁺) antiporter (also known as CLCN7) is localized to the endolysosomal compartments."

Finding 3: CLC-7 Is Expressed in Epithelial Cells but Functions Intracellularly, Not in Transepithelial Transport

A critical question was whether CLC-7 might participate in transepithelial transport in specific epithelial contexts. Targeted investigation of three epithelial tissues where CLC-7 is expressed — ameloblasts (dental epithelium), gastric epithelial cells, and renal tubular cells — revealed that CLC-7's role is always intracellular:

• Ameloblasts: Wen et al. (2015) (PMID: 26346547) showed CLC-7 is expressed in ameloblasts but "located in late endosomes and lysosomes." CLC-7 knockout did not significantly affect enamel mineralization, and CLC-7 was described as "critical for the function of osteoclasts" rather than for transepithelial transport. Separately, Barvencik et al. (2014) (PMID: 25663454) attributed ameloblast tooth defects in CLC-7 knockout mice to osteoclast dysfunction, confirming CLC-7 is "not critical to enamel and dentin formation."
• Gastric epithelium: Weinert et al. (2014) (PMID: 24103576) showed that although CLC-7 is expressed in the stomach, "loss of ClC-7 did not entail a relevant elevation of gastric pH," ruling out a functional role in transepithelial acid/chloride secretion. This distinguishes CLC-7 from the gastric proton pump or other transporters genuinely involved in gastric acid secretion.
• Kidney: Reviews of renal CLC function (PMID: 17477025; PMID: 11053039) consistently identify CLC-K1 (CLC-Ka) and CLC-K2 (CLC-Kb) as the CLC channels mediating transepithelial chloride transport in the kidney, with CLC-5 in intracellular vesicles for endocytosis. CLC-7 is not mentioned as a transepithelial transporter in any renal physiology study.

Finding 4: Sequence Analysis Confirms Lysosomal Sorting Signals and Antiporter Mechanism Distinguish CLCN7 from Transepithelial CLCs

Computational analysis of CLC protein sequences revealed fundamental differences between CLC-7 and the plasma-membrane CLCs that mediate transepithelial transport:

Sorting signals: The CLCN7 N-terminus contains a 126-amino-acid cytoplasmic tail before the first transmembrane helix, harboring multiple endolysosomal sorting motifs:
- Dileucine motif EAAPLL (positions 19–24)
- Second dileucine motif TPLL (positions 33–36)
- Acidic cluster DDEE (positions 16–19)
- DXXLL motif DDELL (positions 65–69)

In contrast, CLCNKA and CLCNKB have short N-termini (~10–51 amino acids) containing zero dileucine or acidic cluster sorting motifs, consistent with their plasma membrane localization. This was experimentally validated by Stauber & Jentsch (2010) (PMID: 20817731), who showed that combined mutation of these N-terminal sorting motifs was required to redirect CLC-7 to the plasma membrane.

Transport mechanism: CLCN7 retains the conserved "gating glutamate" residue characteristic of CLC antiporters, which enables 2Cl⁻/1H⁺ exchange activity. In CLC-Ka and CLC-Kb, this glutamate is replaced by valine, converting the protein into a passive chloride channel — a fundamentally different transport mechanism. Weinert et al. (2010) (PMID: 20430974) demonstrated the functional importance of the antiporter mechanism: "mice carrying a point mutation converting ClC-7 into an uncoupled (unc) Cl⁻ conductor" developed lysosomal storage disease even though lysosomal pH and Cl⁻ conductance were maintained, proving that the Cl⁻/H⁺ exchange stoichiometry — not simple Cl⁻ conductance — is essential for CLC-7 function.

Protein family classification: PANTHER classifies CLCN7 in family PTHR11689 (antiporter) and CLCNKA in PTHR45720 (channel). InterPro assigns CLCN7 to IPR002249 (H⁺/Cl⁻ exchange transporter 7) and CLCNKA to IPR002250 (Chloride channel ClC-K). These separate family assignments reflect deep functional divergence.

Finding 5: IBA Annotation Propagation Mechanism Clarified

Initial analysis hypothesized that the IBA annotation for CLCN7 GO:0030321 was propagated from CLC-Ka/CLC-Kb paralogs within a shared PANTHER family. Detailed investigation revealed a different and more concerning mechanism: PANTHER places CLCN7 and CLCNKA/CLCNKB in entirely separate families (PTHR11689 vs. PTHR45720). The IBA annotation for CLCN7 references PANTHER node PTN002481857 with P51798 (CLCN7 itself) as the seed. This means the IBA propagated within the PTHR11689 antiporter family from CLCN7's own ComplexPortal IDA annotation — the one that misattributed a CLC-family-level introductory sentence to CLC-7 specifically. The result was amplification of a single source error to approximately 1,198 ortholog annotations across many species.

Finding 6: GO:0007042 (Lysosomal Lumen Acidification) Is Recommended as Replacement

Despite strong evidence for CLC-7's role in lysosomal acidification, CLCN7 currently lacks annotations to GO:0007042 (lysosomal lumen acidification) or GO:0007041 (lysosomal transport). These terms are better supported by the primary literature than GO:0030321. CLCN7 already has annotations to GO:1902476 (chloride transmembrane transport) with IBA, IEA, and TAS evidence, which is appropriate but incomplete. GO:0030321 is a child of both GO:0006821 (chloride transport) and GO:0015698 (transepithelial transport) — the "transepithelial" parent is inappropriate for an intracellular transporter. Multiple studies support the replacement: Wang et al. (2021) (PMID: 33495814) demonstrated CLC-7 knockdown "weakened the acidification of lysosomes"; Weinert et al. (2010) (PMID: 20430974) showed lysosomal storage disease upon loss of CLC-7's antiporter function.

Mechanistic Model / Interpretation

CLC Family Functional Architecture

The CLC family has undergone a fundamental functional split that is central to understanding why GO:0030321 is inappropriate for CLC-7:

CLC FAMILY FUNCTIONAL ARCHITECTURE
===================================

PLASMA MEMBRANE CLCs (Channels)          ENDOLYSOSOMAL CLCs (Antiporters)
─────────────────────────────            ────────────────────────────────
CLC-Ka (CLCNKA) ─┐                      CLC-3 ─── endosomes
CLC-Kb (CLCNKB) ─┤ Passive Cl⁻          CLC-4 ─── endosomes
CLC-1  (CLCN1)  ─┤ channels             CLC-5 ─── endosomes
CLC-2  (CLCN2)  ─┘                      CLC-6 ─── late endosomes
                         CLC-7 ─── lysosomes + osteoclast
Key features:                                      ruffled border
• Val at gating position (channel)
• Short N-terminus, no sorting motifs    Key features:
• Basolateral/apical membrane            • Glu at gating position (antiporter)
• Transepithelial Cl⁻ transport ✓        • Long N-terminus with dileucine/
                           acidic cluster sorting motifs
                         • 2Cl⁻/1H⁺ exchange stoichiometry
                         • Intracellular localization
                         • Transepithelial transport ✗

CLC-7 Intracellular Function

┌──────────────────────────────────────────────┐
│                LYSOSOME                       │
│                                               │
│   ┌─────────────┐   ┌─────────────┐          │
│   │  CLC-7/OSTM1│   │  V-ATPase   │          │
│   │  antiporter  │   │             │          │
│   │  2Cl⁻ → lumen│   │  H⁺ → lumen│          │
│   │  1H⁺ ← lumen│   │             │          │
│   └─────────────┘   └─────────────┘          │
│                                               │
│   CLC-7 provides Cl⁻ shunt for V-ATPase     │
│   → enables luminal acidification (pH ~4.5)   │
│   → maintains Cl⁻ homeostasis                │
│   → supports autophagy & degradation         │
└──────────────────────────────────────────────┘

Osteoclast Ruffled Border Context

┌──────────────────────────────────────────────┐
│   OSTEOCLAST RUFFLED BORDER                  │
│                                               │
│   CLC-7/OSTM1 + V-ATPase at ruffled border  │
│   → acidify resorption lacuna (pH ~4.5)      │
│   → dissolve hydroxyapatite                  │
│   → Loss of CLC-7 → osteopetrosis           │
│                                               │
│   NOTE: Ruffled border derives from lysosomal│
│   membrane exocytosis, NOT apical/basolateral│
│   plasma membrane. Osteoclasts are NOT       │
│   epithelial cells (monocyte/macrophage      │
│   lineage).                                   │
└──────────────────────────────────────────────┘

The osteoclast ruffled border deserves special attention because it is the most plasma-membrane-adjacent context for CLC-7. However, the ruffled border is formed by exocytosis of lysosomal vesicles and is topologically distinct from apical/basolateral plasma membrane domains. CLC-7 reaches the ruffled border via its normal lysosomal trafficking pathway, not via plasma membrane targeting. This does not constitute transepithelial transport. Osteoclasts are multinucleated cells derived from the hematopoietic monocyte/macrophage lineage — they are not epithelial cells and do not form an epithelium.

Annotation Provenance Flow

PMID:32851177 abstract sentence (CLC family-level):
  "CLC family proteins... regulate the transepithelial Cl⁻ transport"
 ↓ (misattributed to CLC-7 specifically)
ComplexPortal IDA annotation: clcn7-ostm1_human → GO:0030321
 ↓ (used as seed for PANTHER propagation)
PANTHER IBA annotation: CLCN7 (P51798) → GO:0030321
 ↓ (propagated to orthologs within PTHR11689)
~1,198 IBA annotations across species for CLCN7/OSTM1 orthologs

Direct Gene-Product Activity vs. Downstream Phenotypes

Direct molecular function: CLC-7 is a slowly voltage-gated electrogenic 2Cl⁻/1H⁺ antiporter that exchanges two chloride ions for one proton. This is its direct molecular function, well-established by electrophysiology on plasma-membrane-retargeted CLC-7 mutants (since native CLC-7 is inaccessible to patch-clamp at its endolysosomal location).

Immediate cellular function: CLC-7 accumulates chloride in the lysosomal lumen while removing protons, contributing to lysosomal ion homeostasis. This is coupled to V-ATPase-driven proton pumping to maintain lysosomal acidity and chloride balance.

Downstream phenotypes (NOT direct function — should not guide BP annotation):
- Osteopetrosis (impaired bone resorption due to failed lacuna acidification)
- Lysosomal storage disease (impaired lysosomal degradation)
- Neurodegeneration (secondary to lysosomal dysfunction)
- Coat color changes in mice (melanocyte lysosome-related organelle defects)

Evidence Matrix

Sorting Signal Comparison Table

GO Curation Implications

Recommended Actions (Leads Requiring Curator Verification)

1. REMOVE: GO:0030321 (transepithelial chloride transport) — HIGH PRIORITY

Both annotation sources should be addressed:
- IDA annotation (ComplexPortal, PMID:32851177): The cited paper does not attribute transepithelial transport to CLC-7 specifically. The phrase appears in a family-level introductory sentence. The same paper's abstract states CLC-7 resides in lysosomes and ruffled membranes.
- IBA annotation (PANTHER PTN002481857): Propagated from the flawed IDA above. Removing the IDA root source should allow the IBA propagation (~1,198 ortholog annotations) to be automatically corrected.

2. ADD: GO:0007042 (lysosomal lumen acidification) — HIGH PRIORITY
- Supported by PMID: 33495814 (CLC-7 knockdown impairs lysosomal acidification), PMID: 20430974 (uncoupled mutant causes lysosomal storage disease), PMID: 15706348 (CLC-7 loss causes lysosomal dysfunction).
- Suggested evidence code: IMP (Inferred from Mutant Phenotype).

3. RETAIN: GO:1902476 (chloride transmembrane transport)
- Already annotated with IBA, IEA, TAS. Appropriate as CLC-7 does transport Cl⁻, just not across epithelia.

4. RETAIN: GO:0005765 (lysosomal membrane) — CC
- Already annotated with HDA, EXP, IDA evidence. Well supported.

5. FLAG: PANTHER IBA Propagation for CLC Family Review
- The ~1,198 IBA annotations to GO:0030321 for CLCN7 orthologs across species should be reassessed once the ComplexPortal IDA root source is corrected.

6. CONSIDER: NOT Annotation
- If the GO annotation system supports explicit NOT qualifiers, consider adding NOT|involved_in GO:0030321 for CLCN7 to prevent re-annotation.

GO Decision Table

Conflicts and Alternatives

No Conflicting Evidence Found

Despite extensive targeted searches, no evidence was identified that would support CLC-7 involvement in transepithelial chloride transport:

1. No plasma membrane localization under physiological conditions. CLC-7 reaches the plasma membrane only when its lysosomal sorting motifs are experimentally mutated (PMID: 20817731), or when deliberately engineered with plasma membrane targeting signals for electrophysiological study (PMID: 23983121; PMID: 24159188).

2. No functional transepithelial transport demonstrated. In every epithelial context examined (ameloblasts, gastric epithelium, renal tubules), CLC-7's function is intracellular.

3. No isoform-specific targeting to the plasma membrane. UniProt lists two CLCN7 isoforms (P51798-1, P51798-2); isoform 2 differs at positions 48–71 but key lysosomal sorting motifs (EAAPLL at 19–24, TPLL at 33–36, DDEE at 16–19) are preserved in both. No alternative transcript or isoform has been shown to lack sorting motifs or localize to the plasma membrane.

4. No surface proteomics evidence. No cell-surface proteomics dataset was found reporting CLC-7 at the plasma membrane.

Source of Confusion: CLC Family-Level Statements

Many reviews describe the CLC family as including channels involved in transepithelial transport. When such descriptions are misapplied to individual intracellular CLCs, over-annotation results. This is precisely what happened with the ComplexPortal IDA annotation — a family-level introductory statement in PMID: 32851177 was misattributed to CLC-7 specifically.

Osteoclast Ruffled Border: Not "Transepithelial"

The osteoclast ruffled border is sometimes considered a plasma-membrane-like domain, but:
- Osteoclasts are not epithelial cells; they are multinucleated cells derived from hematopoietic monocyte/macrophage lineage
- The ruffled border is a specialized lysosomal membrane derivative fused with the plasma membrane facing a sealed lacuna
- GO:0030321 specifically requires movement of chloride ions across an epithelium — osteoclasts do not form an epithelium
- Even if the definition were stretched, the ion movement is Cl⁻/H⁺ antiport for lacuna acidification, not vectorial Cl⁻ transport across an epithelial cell layer

Knowledge Gaps

None of these gaps threaten the core conclusion. Even in the unlikely event that a minor isoform or organism-specific variant reaches the plasma membrane, the primary function of human CLCN7 is overwhelmingly established as intracellular endolysosomal Cl⁻/H⁺ exchange.

Proposed Follow-up Experiments / Discriminating Tests

1. Chloride flux assay in polarized epithelial monolayers: CLCN7 knockdown vs. wild-type in MDCK or Caco-2 cells on Transwell inserts, measuring transepithelial Cl⁻ flux. Use CLCNKB knockdown as a positive control. Expected result: no effect from CLCN7 loss.

2. Surface biotinylation of CLC-7 in polarized epithelial cells: Cell-surface biotinylation followed by streptavidin pulldown and CLC-7 Western blot in multiple epithelial cell lines. Would directly test whether endogenous CLC-7 is ever present at the cell surface. Expected result: CLC-7 absent from surface fraction.

3. BioID/APEX2 proximity labeling: CLC-7 fused to a proximity labeling enzyme, followed by proteomics to identify neighboring proteins. If all neighbors are lysosomal/endosomal markers, this confirms intracellular localization.

4. Single-cell RNA-seq + Human Protein Atlas cross-reference: Compare CLCN7 expression across all epithelial cell types with Human Protein Atlas subcellular localization data to confirm universal intracellular localization pattern.

5. ComplexPortal curator contact: Flag the IDA annotation for the clcn7-ostm1_human complex with GO:0030321 (PMID:32851177) as a misattribution for curator review and correction.

Curation Leads

Lead 1: Remove GO:0030321 from CLCN7 (HIGH PRIORITY)

• Action: Remove both IDA and IBA annotations for GO:0030321 (transepithelial chloride transport)
• Rationale: No experimental evidence supports this annotation. All localization data places CLC-7 in lysosomes/late endosomes. The IDA citation (PMID:32851177) contains a CLC-family-level introductory statement misattributed to CLC-7 specifically.
• Candidate references to verify:
• PMID: 20817731 — "ClC-7 could be partially shifted from lysosomes to the plasma membrane by combined mutation of N-terminal sorting motifs" — confirms normal localization is NOT plasma membrane
• PMID: 17110406 — "the intracellular localization of ClC-6 and ClC-7/Ostm1 precluded biophysical studies" — CLC-7 is intracellular
• PMID: 16525474 — "both ClC-7 and Ostm1 proteins co-localize in late endosomes and lysosomes of various tissues, as well as in the ruffled border of bone-resorbing osteoclasts" — definitive localization

Lead 2: Add GO:0007042 (Lysosomal Lumen Acidification) to CLCN7 (HIGH PRIORITY)

• Action: Add BP annotation with IMP evidence
• Reference to verify: PMID: 20430974 — "We generated mice carrying a point mutation converting ClC-7 into an uncoupled (unc) Cl⁻ conductor. Despite maintaining lysosomal conductance and normal lysosomal pH, these Clcn7(unc/unc) mice showed lysosomal storage disease like mice lacking ClC-7"
• Additional reference: PMID: 33495814 — CLC-7 knockdown weakened lysosomal acidification

Lead 3: Flag ~1,198 IBA Ortholog Annotations for Reassessment (MEDIUM PRIORITY)

• Action: After IDA source is removed, PANTHER IBA annotations propagated from PTN002481857 for GO:0030321 should be flagged for reassessment
• Scope: Affects CLCN7 orthologs across many species

Lead 4: Flag ComplexPortal IDA Annotation as Misattributed

• Action: Contact ComplexPortal to review the IDA annotation for the clcn7-ostm1_human complex with GO:0030321 citing PMID:32851177
• Rationale: The cited paper's mention of "transepithelial Cl⁻ transport" is a family-level introductory statement; the paper's specific findings do not support this function for CLC-7

Suggested Questions for Curator

1. Does the ComplexPortal entry for CLC-7/OSTM1 need to be corrected to remove the GO:0030321 annotation at the source?
2. Should the PANTHER family node PTN002481857 be reviewed to prevent re-propagation?
3. Is GO:0007042 (lysosomal lumen acidification) sufficiently specific, or should a more precise term be considered?
4. Should a NOT annotation (NOT involved_in GO:0030321) be added to prevent future re-annotation?

Evidence Base: Key Literature

Report generated 2026-06-21. Based on analysis of 37 papers, computational sequence analysis, and database annotation provenance tracing across 3 investigation iterations.

Artifacts

• OpenScientist final report
• OpenScientist final report